{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:23:46Z","timestamp":1787315026605,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.numecd.2026.104929","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:26:47Z","timestamp":1785367607000},"page":"104929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular and renal protection of SGLT2i in early-stage type 2 diabetes: the DIAB-CV-AP study"],"prefix":"10.1016","author":[{"given":"Jorge","family":"Pablo-Ortega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Portela-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Maz\u00f3n-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Segura-Fragoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rey-Aldana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose R.","family":"Gonz\u00e1lez-Juanatey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4486-2820","authenticated-orcid":false,"given":"Sergio","family":"Cinza-Sanjurjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2026.104929_bib1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death","volume":"364","author":"Rao Kondapally Seshasai","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2026.104929_bib2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jama.2015.7008","article-title":"Association of cardiometabolic multimorbidity with mortality","volume":"314","author":"Di Angelantonio","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2026.104929_bib3","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S2213-8587(23)00223-1","article-title":"Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observation","volume":"11","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.numecd.2026.104929_bib4","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2026.104929_bib5","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2026.104929_bib6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2019","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"10.1016\/j.numecd.2026.104929_bib7","article-title":"6. Glycemic goals, hypoglycemia, and hyperglycemic crises: standards of Care in Diabetes\u20142026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2026.104929_bib8","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.2337\/dc25-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of Care in Diabetes\u20142025","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2026.104929_bib9","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2026.104929_bib10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2026.104929_bib11","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2026.104929_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2026.104929_bib13","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2026.104929_bib14","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2026.104929_bib15","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.numecd.2026.104929_bib16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study","volume":"8","author":"Heerspink","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.numecd.2026.104929_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2022.101418","article-title":"Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study","volume":"49","author":"Karasik","year":"2023","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.numecd.2026.104929_bib18","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2026.104929_bib19","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.mayocp.2023.01.023","article-title":"SGLT2 inhibitors are associated with reduced cardiovascular disease in patients with type 2 diabetes: an analysis of real-world data","volume":"98","author":"Wang","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.numecd.2026.104929_bib20","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.032397","article-title":"Sodium glucose transporter 2 inhibitors versus metformin on cardiovascular and renal outcomes in patients with diabetes with low cardiovascular risk: a nationwide cohort study","volume":"13","author":"Chang","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.numecd.2026.104929_bib21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/dom.15625","article-title":"Detecting and managing the patient with chronic kidney disease in primary care: a review of the latest guidelines","volume":"26","author":"Mayne","year":"2024","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.numecd.2026.104929_bib22","doi-asserted-by":"crossref","first-page":"432","DOI":"10.30574\/gscarr.2024.21.3.0507","article-title":"Risk factors for chronic kidney disease in primary care: a comprehensive review","volume":"21","author":"Daminov","year":"2024","journal-title":"GSC Adv Res Rev"},{"key":"10.1016\/j.numecd.2026.104929_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.semerg.2025.102667","article-title":"SGLT2i compared to other non-insulin antidiabetics in primary care patients with earlier diabetes. Cohort profile and sample characteristics of DIAB-CV-AP study","volume":"52","author":"Pablo-Ortega","year":"2026","journal-title":"Semergen"},{"key":"10.1016\/j.numecd.2026.104929_bib24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.numecd.2026.104929_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105175","article-title":"SGLT2 inhibitors for prevention of cardiorenal events in people with type 2 diabetes without cardiorenal disease: a meta-analysis of large randomized trials and cohort studies","volume":"161","author":"Qiu","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.numecd.2026.104929_bib26","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2026.104929_bib27","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1007\/s00125-022-05773-8","article-title":"SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits","volume":"65","author":"Marilly","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.numecd.2026.104929_bib28","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/dom.14374","article-title":"Sodium-glucose co-transporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis","volume":"23","author":"Giugliano","year":"2021","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.numecd.2026.104929_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-077097","article-title":"Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data","volume":"385","author":"Bidulka","year":"2024","journal-title":"Br Med J"},{"key":"10.1016\/j.numecd.2026.104929_bib30","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030578","article-title":"Sodium-glucose cotransporter-2 inhibitors and primary prevention of atherosclerotic cardiovascular disease: a meta-analysis of randomized trials and systematic review","volume":"12","author":"Rahman","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.numecd.2026.104929_bib31","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1111\/dom.15226","article-title":"Cardiovascular prevention with glucose-lowering drugs in type 2 diabetes: an evidence-based approach to the categories of primary and secondary prevention","volume":"25","author":"Mannucci","year":"2023","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.numecd.2026.104929_bib32","article-title":"Cardiovascular and renal outcomes among patients with type 2 diabetes using SGLT2 inhibitors added to metformin: a population-based cohort study from the UK","volume":"11","author":"Perez","year":"2023","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.numecd.2026.104929_bib33","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2026.104929_bib34","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.numecd.2026.104929_bib35","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1007\/s00125-021-05407-5","article-title":"Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial","volume":"64","author":"Cherney","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.numecd.2026.104929_bib36","doi-asserted-by":"crossref","first-page":"417","DOI":"10.7326\/M20-0289","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis","volume":"173","author":"Douros","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.numecd.2026.104929_bib37","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study","volume":"363","author":"Ueda","year":"2018","journal-title":"Br Med J"},{"key":"10.1016\/j.numecd.2026.104929_bib38","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/eurjpc\/zwad356","article-title":"Sodium-glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis","volume":"31","author":"Zhang","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.numecd.2026.104929_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112320","article-title":"Efficacy and safety of SGLT-2 inhibitors in patients with comorbid type 2 diabetes and atrial fibrillation: a meta-analysis","volume":"226","author":"Tang","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.numecd.2026.104929_bib40","doi-asserted-by":"crossref","first-page":"267","DOI":"10.14740\/jocmr3761","article-title":"Renoprotective effects of additional SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and chronic kidney disease stages 3b-4: a real world report from a Japanese specialized diabetes care center","volume":"11","author":"Sugiyama","year":"2019","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.numecd.2026.104929_bib41","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/ajh\/hpae092","article-title":"State-of-the-art review: mechanisms of action of SGLT2 inhibitors and clinical implications","volume":"37","author":"Vallon","year":"2024","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.numecd.2026.104929_bib42","doi-asserted-by":"crossref","first-page":"C525","DOI":"10.1152\/ajpcell.00143.2024","article-title":"Mechanisms of heart failure and chronic kidney disease protection by SGLT2 inhibitors in nondiabetic conditions","volume":"327","author":"Girardi","year":"2024","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.numecd.2026.104929_bib43","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/dom.14599","article-title":"Challenges and opportunities in real-world evidence on the renal effects of sodium-glucose cotransporter-2 inhibitors","volume":"24","author":"Fadini","year":"2022","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.numecd.2026.104929_bib44","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.36613","article-title":"Second-line pharmaceutical treatments for patients with type 2 diabetes","volume":"6","author":"Vashisht","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.numecd.2026.104929_bib45","article-title":"Does combination therapy with SGLT2 inhibitors and renin-angiotensin system blockers lead to greater reduction in cardiorenal events among patients with type 2 diabetes?","volume":"8","author":"Zhao","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.numecd.2026.104929_bib46","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s41100-020-00303-x","article-title":"Two Japanese patients with stage G3b chronic kidney disease and impaired glucose metabolism after renal transplantation successfully treated with empagliflozin","volume":"6","author":"Miyazaki","year":"2020","journal-title":"Ren Replace Ther"},{"key":"10.1016\/j.numecd.2026.104929_bib47","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12882-022-02793-9","article-title":"Empagliflozin in kidney transplant recipients with chronic kidney disease G3a-4 and metabolic syndrome: five Japanese cases","volume":"23","author":"Miyazaki","year":"2022","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.numecd.2026.104929_bib48","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1093\/ehjcvp\/pvab039","article-title":"SGLT2 inhibitors in cardiovascular medicine","volume":"7","author":"Varzideh","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.numecd.2026.104929_bib49","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3949\/ccjm.88a.20088","article-title":"The role of SGLT-2 inhibitors in managing type 2 diabetes","volume":"88","author":"Tsushima","year":"2021","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.numecd.2026.104929_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.103","article-title":"The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: design and exposure accrual for an evaluation of empagliflozin in routine clinical care","volume":"3","author":"Patorno","year":"2020","journal-title":"Endocrinol Diabetes Metab"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475326003911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475326003911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:37:07Z","timestamp":1787312227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475326003911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":50,"alternative-id":["S0939475326003911"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2026.104929","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular and renal protection of SGLT2i in early-stage type 2 diabetes: the DIAB-CV-AP study","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2026.104929","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104929"}}